Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (CAT#: GTTS-WQ11813MR)

This product GTTS-WQ11813MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Breast Cancer, Colorectal Cancer (CRC), Non-Small Cell Lung Cancers (NSCLC), Gastric Cancer research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP
5' Cap	Cap 0
Species	Humanized
RefSeq	NM_005018.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	5133
UniProt ID	Q15116

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11813MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ12256MR	IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, Pseudo-UTP, 30 nt-poly(A))	mRNA	MRA
GTTS-WQ13999MR	IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	REGN-3470-3471-3479
GTTS-WQ11685MR	IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	MHAB5553A
GTTS-WQ6483MR	IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	CT-P-59
GTTS-WQ6038MR	IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	CNTO 136
GTTS-WQ2660MR	IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, Pseudo-UTP, 30 nt-poly(A))	mRNA	AMG 655
GTTS-WQ15613MR	IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	VAY-736
GTTS-WQ11455MR	IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	MEDI-9447

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST